[go: up one dir, main page]

MX2018012410A - Metodos para tratar enfermedades inflamatorias. - Google Patents

Metodos para tratar enfermedades inflamatorias.

Info

Publication number
MX2018012410A
MX2018012410A MX2018012410A MX2018012410A MX2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A
Authority
MX
Mexico
Prior art keywords
methods
inflammatory diseases
treat inflammatory
diseases
psoriasis
Prior art date
Application number
MX2018012410A
Other languages
English (en)
Other versions
MX392703B (es
Inventor
Bettina Galler Annette
John Padula Steven
Ruth Flack Mary
Lalovic Bojan
Visvanathan Sudha
Scholl Paul
Baum Patrick
MAINO Kaori
SHA Koji
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018012410A publication Critical patent/MX2018012410A/es
Publication of MX392703B publication Critical patent/MX392703B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Esta invención se refiere generalmente a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como psoriasis o artritis psoriásica, que utilizan anticuerpos anti-IL-23A.
MX2018012410A 2016-04-15 2017-04-13 Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada. MX392703B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323075P 2016-04-15 2016-04-15
US201662336815P 2016-05-16 2016-05-16
US201662396855P 2016-09-20 2016-09-20
US201662400116P 2016-09-27 2016-09-27
US201762463959P 2017-02-27 2017-02-27
PCT/US2017/027332 WO2017180821A1 (en) 2016-04-15 2017-04-13 Methods of treating inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2018012410A true MX2018012410A (es) 2019-02-21
MX392703B MX392703B (es) 2025-03-19

Family

ID=58633116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012410A MX392703B (es) 2016-04-15 2017-04-13 Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.

Country Status (7)

Country Link
US (3) US20170298126A1 (es)
EP (5) EP3560956A3 (es)
JP (2) JP6728392B2 (es)
AU (2) AU2017250583A1 (es)
CA (1) CA3018794A1 (es)
MX (1) MX392703B (es)
WO (1) WO2017180821A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
CA3081343A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
KR20220016954A (ko) * 2019-06-04 2022-02-10 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
WO2023133538A2 (en) * 2022-01-07 2023-07-13 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
TW202540171A (zh) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Ｉｌ－２３抗體組合物及使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3704137A1 (de) 1986-11-05 1988-05-11 Kok Schram De Jong Marijke Ire Anordnung zur bildlichen darstellung unter verwendung von holographischen folien
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
CN101389351B (zh) 2005-12-29 2012-10-10 森托科尔公司 人抗il-23抗体、组合物、方法和用途
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
CN104507497B (zh) * 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
WO2016014775A1 (en) * 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
IL307578A (en) * 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases

Also Published As

Publication number Publication date
MX392703B (es) 2025-03-19
WO2017180821A1 (en) 2017-10-19
JP2020172508A (ja) 2020-10-22
US20170298126A1 (en) 2017-10-19
JP2019511532A (ja) 2019-04-25
US20200308271A1 (en) 2020-10-01
CA3018794A1 (en) 2017-10-19
EP3744733A2 (en) 2020-12-02
EP3560956A2 (en) 2019-10-30
EP3974451A3 (en) 2022-07-06
AU2024203978A1 (en) 2024-07-04
AU2017250583A1 (en) 2018-08-16
EP3744733A3 (en) 2021-02-24
US20250304674A1 (en) 2025-10-02
EP4410997A3 (en) 2024-11-13
EP3443005A1 (en) 2019-02-20
EP3974451A2 (en) 2022-03-30
EP3560956A3 (en) 2020-01-01
JP6728392B2 (ja) 2020-07-22
EP4410997A2 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2018012410A (es) Metodos para tratar enfermedades inflamatorias.
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
UY37018A (es) Inhibidores bicíclicos de pad4
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112017025003A2 (pt) composições compreendendo cepas bacterianas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
CR20150466A (es) Péptidos y composiciones para el tratamiento de daño articular
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CO2020012169A2 (es) Compuestos de aminopirazina diol como inhibidores de pi3k-y
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX2019009304A (es) Tratamiento para el cancer.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
CO2018004493A2 (es) Métodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f)
MX385854B (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
MX2019000539A (es) Anticuerpos anti-il-22r.
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
CL2017002304A1 (es) Métodos para tratar enfermedades
BR112017025264A2 (pt) tratamento de prurido
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.